Back to Top Skip to main content

DoD Pharmacy & Therapeutics Committee

The Department of Defense Pharmacy & Therapeutics (DoD P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DoD beneficiaries in an effective, efficient, and fiscally responsible manner. 

To learn more, please see the Dec 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified 22 Mar 2005).

DoD P&T Committee Meeting Schedule

View DoD P&T Meeting Minutes See Archived Meeting Pages



May 6-7, 2020

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: January 30, 2020
  • Pre-Proposal Teleconference: February 12, 2020  @ 1300 Central 
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Quotes Due: March 27, 2020   

 

Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • PSORIASIS AGENTS - NA:
    • Calcitriol
    • Calcitrene
    • Calcipotriene Clobetasol Propionate
    • Calcipotriene Monohydrate
    • Dovonex
    • Enstilar
    • Oxsoralen-Ultra
    • Soriatane
    • Sorilux
    • Taclonex
    • Tazorac
    • Vectical
  • SLEEP DISORDERS - WAKEFULNESS PROMOTING AGENTS:
    • Nuvigil
    • Provigil
    • Sunosi
    • Wakix
    • Xyrem
  • WHITE BLOOD CELL STIMULANTS - FILGRASTIMS:
    • Granix
    • Neupogen
    • Nivestym
    • Zarxio
  • WHITE BLOOD CELL STIMULANTS - PEGFILGRASTIMS:
    • Fulphila
    • Neulasta
    • Udenyca
    • Ziextenzo

Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions.

   

February 5-6, 2020

Uniform Formulary Request for Quote Information

  • UF BPA & UF ADP RFQ Documents Posted: November 1, 2019
  • Pre-Proposal Teleconference: November 13 2019 @ 1200 Central 
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Quotes Due: December 20, 2019  

 

Class Review  Designated Newly Approved Drugs Drugs in Previously Reviewed Classes 
  • PAIN AGENTS - NSAID:
    • Duexis
    • Qmiiz ODT
    • Sprix
    • Tivorbex
    • Vimovo
    • Vivlodex
    • Zipsor
    • Zorvolex
    • Anaprox DS, generics
    • Ansaid, generics
    • Arthrotec, generics
    • Cambia, generics
    • Cataflam, generics
    • Celebrex, generics
    • Choline magnesium trisalicylate, generics
    • Clinoril, generics
    • Daypro, generics
    • Diflunisal, generics
    • Disalcid, generics
    • Dyloject, generics
    • Feldene, generics
    • Fenortho, generics
    • Ibu, generics
    • Indocin IR, generics
    • Indocin ER, generics
    • Indocin Rectal, generics
    • Indocin Suspension, generics
    • Lodine, generics
    • Lodine XL, generics
    • Meclomen, generics
    • Mobic, generics
    • Nalfon, generics
    • Naprelan CR, generics
    • Naproxen IR, generics
    • Naproxen DR, generics
    • Naproxen Suspension, generics
    • Orudis, generics
    • Oruvail, generics
    • Ponstel, generics
    • Profeno, generics
    • Relafen, generics
    • Tolectin, generics
    • Toradol cartridge, generics
    • Toradol syringe, generics
    • Toradol tablet, generics
    • Toradol vial, generics
    • Voltaren DR, generics
    • Voltaren XR tablet, generics
  • PAIN AGENTS - PAIN TOPICAL:
    • Diclofono
    • Flector, generics
    • Lidoderm, generics
    • Pennsaid drops, generics
    • Pennsaid Pump
    • Voltaren, generics
    • ZTLido
  • Aklief
  • Amzeeq
  • Brukinsa
  • Consensi
  • Enzoclear
  • Fasenra Pen
  • Gloperba
  • Jatenzo
  • Oxbryta
  • Ozobax
  • Pretomanid
  • Proair Digihaler
  • Secuado
  • Talicia
  • Trikafta
  • Vumerity
  • Ziextenzo
 

Subject to Change Disclaimer

The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

If the DoD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.

Decision Papers

File Date
Decision Paper on Implementing ESI Commercial Reject List and Prior Authorization for all Compound Medication Prescriptions 5/8/2015

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing | Download a PDF Reader or learn more about PDFs.